Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Terminated
Slow recruitment
Other terminated trials from McGill University Health Centre/Research Institute of the McGill University Health Centre
Other Interstitial Lung Disease trials with similar outcome
This NA trial investigates Interstitial Lung Disease and Myopathy, Inflammatory and is currently terminated or withdrawn. McGill University Health Centre/Research Institute of the McGill University Health Centre leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Oct 2025 — Present [monthly]
Terminated NA
Status: Unknown → Terminated
-
Sep 2025 — Oct 2025 [monthly]
Unknown NA
-
Sep 2024 — Sep 2025 [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
May 2024 — Jul 2024 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
▶ Show 1 earlier version
-
May 2022 — May 2024 [monthly]
Recruiting NA
First recorded
Jun 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- McGill University Health Centre/Research Institute of the McGill University Health Centre
For direct contact, visit the study record on ClinicalTrials.gov .